Catalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $33 from $32 and keeps an Outperform rating on the shares. The firm notes the company reported Q3 total revenue of $148.4M, coming in well above its/consensus estimates of $136M/$137M and driving non-GAAP net income of $86.1M.